Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence and Consensus Based Guidelines for Imaging in Tubercular Choroiditis. Multimodal imaging in Uveitis (MUV) Taskforce: Report 17.

Ophthalmology. Retina·2026
Same author

Evidence and Consensus-Based Guidelines in Vogt-Koyanagi-Harada Disease. Multimodal Imaging in Uveitis (MUV) Taskforce Report 16.

Ophthalmology. Retina·2026
Same author

Evidence and Consensus-Based Imaging Guidelines in Cytomegalovirus Retinitis: Multimodal Imaging in Uveitis (MUV) Task Force - Report 15.

Ophthalmology. Retina·2026
Same author

Combination of Ocular Radiation With Systemic Chemotherapy for Treatment of Primary Vitreoretinal Lymphoma: A Prospective Single Center Cohort With Long Follow-Up.

American journal of hematology·2026
Same author

The Multimodal Imaging in Uveitis Virtual Special Issue.

American journal of ophthalmology·2026
Same author

Nasal Retinal Degeneration Is a Feature of a Subset of <i>CRX</i>-Associated Retinopathies.

Genes·2026

Related Experiment Video

Updated: Jun 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab in inflammatory eye disease.

McGregor N Lott1, Joyce C Schiffman, Janet L Davis

  • 1Bascom Palmer Eye Institute, Miami, FL, USA. mcgnlott@aol.com

American Journal of Ophthalmology
|August 8, 2009
PubMed
Summary

Intravitreal bevacizumab (Avastin) injections helped stabilize visual acuity and macular thickness in patients with inflammatory choroidal neovascularization (CNV) or cystoid macular edema (CME). This suggests bevacizumab may be a viable treatment option for these conditions.

Related Experiment Videos

Last Updated: Jun 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Vascular Biology

Background:

  • Inflammatory choroidal neovascularization (CNV) and cystoid macular edema (CME) are significant causes of vision loss.
  • Intravitreal anti-vascular endothelial growth factor (VEGF) agents are commonly used to treat neovascular and edematous retinal conditions.

Purpose of the Study:

  • To evaluate the efficacy of intravitreal bevacizumab (Avastin) in improving visual acuity (VA) and reducing macular thickness in patients with inflammatory CNV or CME.
  • To assess the long-term effects of bevacizumab treatment on these ocular conditions.

Main Methods:

  • A retrospective, noncomparative, interventional case series was conducted.
  • Thirty-four eyes of 30 patients with inflammatory CNV or CME received intravitreal bevacizumab (1.25 mg) at baseline.
  • Best-corrected visual acuity (BCVA) and central subfield thickness (CST) via optical coherence tomography (OCT) were monitored at regular intervals.

Main Results:

  • In the CNV group (21 eyes), BCVA significantly improved at month 1 post-injection but returned to baseline levels thereafter. Central subfield thickness (CST) remained stable.
  • In the CME group (13 eyes), neither BCVA nor CST showed significant changes from baseline throughout the follow-up period.
  • Patients received a median of two bevacizumab injections, with follow-up durations ranging from 1 to 28 months.

Conclusions:

  • Intravitreal bevacizumab appears to stabilize best-corrected visual acuity (BCVA) and central subfield thickness (CST) in eyes with inflammatory choroidal neovascularization (CNV) or cystoid macular edema (CME).
  • Bevacizumab may serve as a valuable therapeutic option for managing these inflammatory retinal conditions.